1417 RESULTS
CONFERENCE COVERAGE 2025-02-15 Conference Coverage Although efforts to identify biomarkers for Alzheimer's disease are advancing rapidly, many still struggle to obtain information from populations other than non-Hispanic white people. At the Human Amyloid Imaging (HAI) conference,
CONFERENCE COVERAGE 2025-02-15 Conference Coverage When it comes to tau tangles, cortical deposits receive the lion’s share of scientists’ attention, but it is the tiny subcortical regions where tangles originate that might set the course for Alzheimer's. New data presented at the
CONFERENCE COVERAGE 2025-02-14 Conference Coverage The hunt for blood-based biomarkers is continuing apace. At the Human Amyloid Imaging (HAI) meeting, held January 15-17, researchers focused on new techniques—all based on tau and blood, conference title notwithstanding—for identifying
CONFERENCE COVERAGE 2024-11-27 Conference Coverage As diagnostic criteria for Alzheimer’s disease are being refined, the U.S. and Europe have taken different paths. Broadly speaking, leading clinicians in the U.S. use Alzheimer’s Association criteria, while those in Europe hew to recom
CONFERENCE COVERAGE 2024-11-26 Conference Coverage Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s Disease meeting, held last month in Madri
CONFERENCE COVERAGE 2024-11-22 Conference Coverage What if there were a way to triple the speed of MRI scans without losing resolution? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Miguel Rosa-Grilo of University College London pres
CONFERENCE COVERAGE 2024-11-22 Conference Coverage Most Alzheimerologists agree that lecanemab and donanemab are a start, but insufficient to treat this disease. At the Clinical Trials in Alzheimer’s Disease conference, held last month in Madrid, scientists not only debated how to make
CONFERENCE COVERAGE 2024-11-21 Conference Coverage Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In answering a question that has been ra
CONFERENCE COVERAGE 2024-11-15 Conference Coverage Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October 29-November 1 in Madrid, speakers upda
CONFERENCE COVERAGE 2024-11-14 Conference Coverage While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on Alzheimer’s Disease conference, held Oct
CONFERENCE COVERAGE 2024-11-14 Conference Coverage The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma presented the first signal that a monoclona
CONFERENCE COVERAGE 2024-11-14 Conference Coverage Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 through November 1 in Madrid, speakers o
CONFERENCE COVERAGE 2024-11-08 Conference Coverage Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease conference, held October 29-Nov
CONFERENCE COVERAGE 2024-11-08 Conference Coverage Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of hazardous brain bleeding, reflected i
CONFERENCE COVERAGE 2024-09-19 Conference Coverage Alzheimer’s is a multifaceted disease, particularly in its sporadic, late-onset form. Myriad factors—genetics, environment, cardiovascular health, metabolism, and inflammation—contribute to a decades-long process. Generating animal mod
